Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 7/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | RARG | P13631 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20887712 | 1.00 | BRD4 (0.51) | BRD4PDK2KDM4ETSHRGAA | |
| SCHEMBL29596450 | 0.91 | BRD4 (0.50) | BRD4PDK2KDM4ETSHRGAA | |
| SCHEMBL20887580 | 0.91 | BRD4 (0.50) | BRD4PDK2KDM4ETSHRGAA | |
| SCHEMBL20876267 | 0.87 | BRD4 (0.50) | BRD4ALOX5PTGS1PTGS2 | |
| SCHEMBL20887641 | 0.84 | BRD4 (0.71) | BRD4PDK2 | |
| SCHEMBL29596236 | 0.84 | BRD4 (0.71) | BRD4PDK2 | |
| SCHEMBL29595716 | 0.84 | BRD4 (0.71) | BRD4PDK2 | |
| SCHEMBL20887713 | 0.84 | BRD4 (0.71) | BRD4PDK2 | |
| SCHEMBL20887636 | 0.84 | BRD4 (0.71) | BRD4PDK2 | |
| SCHEMBL20876245 | 0.83 | BRD4 (0.57) | BRD4PDK2KDM4ETSHRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885PDK2 963/4885KDM4E 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.